CA Stock MarketDetailed Quotes

DOSE Rapid Dose Therapeutics Corp

Watchlist

0.150
0.0000.00%

15min DelayMarket Closed Sep 26 09:30 ET

18.70MMarket Cap-3750P/E (TTM)

Rapid Dose Therapeutics Corp Key Stats

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(Q1)May 31, 2024

(FY)Feb 29, 2024

(Q4)Feb 29, 2024

(Q3)Nov 30, 2023

(Q2)Aug 31, 2023

(Q1)May 31, 2023

(FY)Feb 28, 2023

(Q4)Feb 28, 2023

(Q3)Nov 30, 2022

(Q2)Aug 31, 2022

Total revenue

65.70%398.99K

42.06%1.02M

-11.36%192.65K

-23.50%233.81K

164.44%353.17K

289.84%240.79K

-59.00%718.3K

49.07%217.35K

-33.23%305.63K

-58.86%133.55K

Operating revenue

65.70%398.99K

42.06%1.02M

-11.36%192.65K

-23.50%233.81K

164.44%353.17K

289.84%240.79K

-59.00%718.3K

49.07%217.35K

-33.23%305.63K

-58.86%133.55K

Cost of revenue

15.51%142.29K

32.13%457.02K

-53.44%87.86K

33.62%104.42K

124.38%109.23K

305.56%123.18K

-15.04%345.89K

-17.79%188.7K

-20.71%78.14K

48.88%48.68K

Gross profit

118.28%256.7K

51.29%563.41K

265.76%104.8K

-43.12%129.4K

187.42%243.95K

274.62%117.61K

-72.31%372.4K

134.22%28.65K

-36.66%227.49K

-70.93%84.87K

Operating expense

100.21%1.21M

-7.03%3.64M

8.15%1.29M

32.77%1.01M

-16.51%800.35K

-40.06%604.85K

-30.65%3.92M

-56.90%1.19M

-32.02%759.14K

0.64%958.65K

Selling and administrative expenses

151.85%1.1M

-17.95%2.6M

-3.43%781.55K

22.92%754.68K

-29.89%626.1K

-48.73%436.26K

-29.95%3.17M

-64.59%809.3K

-31.55%613.99K

27.31%893.06K

-Selling and marketing expense

143.50%228.96K

-14.86%241.7K

-154.08%-67.35K

555.36%183.06K

45.10%109.12K

68.00%94.03K

-4.12%283.89K

-49.55%124.54K

79.89%27.93K

248.14%75.2K

-General and administrative expense

154.14%869.75K

-18.26%2.36M

23.97%848.9K

-2.46%571.62K

-36.79%516.98K

-56.95%342.23K

-31.76%2.88M

-66.41%684.76K

-33.52%586.06K

20.29%817.86K

Research and development costs

33.68%29.52K

360.57%427.8K

351.53%303.41K

202.76%100.37K

103.88%1.94K

-48.10%22.08K

-74.15%92.89K

-59.61%67.2K

-50.43%33.15K

-150.91%-50K

Depreciation amortization depletion

-43.53%82.73K

-1.14%620.31K

-27.09%207.25K

36.46%152.84K

21.28%140.19K

26.75%146.51K

-18.07%627.44K

-7.59%284.26K

-26.73%112K

-24.38%115.59K

-Depreciation and amortization

-43.53%82.73K

-1.14%620.31K

-27.09%207.25K

36.46%152.84K

21.28%140.19K

26.75%146.51K

-18.07%627.44K

-7.59%284.26K

-26.73%112K

-24.38%115.59K

Provision for doubtful accounts

----

-145.89%-5.97K

----

--13K

----

Other operating expenses

----

--32.12K

----

--15.62K

----

Operating profit

-95.85%-954.25K

13.16%-3.08M

-1.79%-1.18M

-65.24%-878.49K

36.32%-556.4K

50.16%-487.25K

17.62%-3.54M

59.17%-1.16M

29.82%-531.65K

-32.27%-873.77K

Net non-operating interest income (expenses)

-281.80%-304.03K

-149.94%-661.45K

-115.80%-304.95K

-97.86%-102.59K

-327.70%-174.28K

-159.11%-79.63K

-98.80%-264.64K

-297.35%-141.31K

-68.70%-51.85K

-21.14%-40.75K

Non-operating interest expense

281.80%304.03K

149.94%661.45K

115.80%304.95K

97.86%102.59K

----

159.11%79.63K

98.26%264.64K

297.89%141.31K

67.77%51.85K

----

Total other finance cost

----

327.70%174.28K

----

--40.75K

Other net income (expenses)

-35,162.05%-567.72K

99.96%-1.61K

Gain on sale of security

----

-453.11%-8.91K

----

-106.73%-1.61K

----

Special income (charges)

----

---558.81K

----

--0

----

-Less:Other special charges

----

--558.81K

----

Income before tax

-121.97%-1.26M

-13.03%-4.31M

-57.57%-2.05M

-68.14%-981.08K

20.10%-730.69K

43.79%-566.88K

55.11%-3.81M

81.18%-1.3M

26.21%-583.5K

-31.73%-914.52K

Income tax

Earnings from equity interest net of tax

Net income

-121.97%-1.26M

-13.03%-4.31M

-57.57%-2.05M

-68.14%-981.08K

20.10%-730.69K

43.79%-566.88K

55.11%-3.81M

81.18%-1.3M

26.21%-583.5K

-31.73%-914.52K

Net income continuous operations

-121.97%-1.26M

-13.03%-4.31M

-57.57%-2.05M

-68.14%-981.08K

20.10%-730.69K

43.79%-566.88K

55.11%-3.81M

81.18%-1.3M

26.21%-583.5K

-31.73%-914.52K

Noncontrolling interests

Net income attributable to the company

-121.97%-1.26M

-13.03%-4.31M

-57.57%-2.05M

-68.14%-981.08K

20.10%-730.69K

43.79%-566.88K

55.11%-3.81M

81.18%-1.3M

26.21%-583.5K

-31.73%-914.52K

Preferred stock dividends

Other under preferred stock dividend

Net income attributable to common stockholders

-121.97%-1.26M

-13.03%-4.31M

-57.57%-2.05M

-68.14%-981.08K

20.10%-730.69K

43.79%-566.88K

55.11%-3.81M

81.18%-1.3M

26.21%-583.5K

-31.73%-914.52K

Diluted earnings per share

0.00%-0.01

0.00%-0.04

37.50%-0.01

-66.67%-0.01

0.00%-0.01

50.00%-0.04

75.38%-0.016

25.00%-0.006

0.00%-0.01

Basic earnings per share

0.00%-0.01

0.00%-0.04

37.50%-0.01

-66.67%-0.01

0.00%-0.01

50.00%-0.04

75.38%-0.016

25.00%-0.006

0.00%-0.01

Dividend per share

Accounting Standards

US-GAAP

Audit Opinions

Unqualified Opinion with Explanatory Notes

	(Q1)May 31, 2024	(FY)Feb 29, 2024	(Q4)Feb 29, 2024	(Q3)Nov 30, 2023	(Q2)Aug 31, 2023	(Q1)May 31, 2023	(FY)Feb 28, 2023	(Q4)Feb 28, 2023	(Q3)Nov 30, 2022	(Q2)Aug 31, 2022
Total revenue	65.70%398.99K	42.06%1.02M	-11.36%192.65K	-23.50%233.81K	164.44%353.17K	289.84%240.79K	-59.00%718.3K	49.07%217.35K	-33.23%305.63K	-58.86%133.55K
Operating revenue	65.70%398.99K	42.06%1.02M	-11.36%192.65K	-23.50%233.81K	164.44%353.17K	289.84%240.79K	-59.00%718.3K	49.07%217.35K	-33.23%305.63K	-58.86%133.55K
Cost of revenue	15.51%142.29K	32.13%457.02K	-53.44%87.86K	33.62%104.42K	124.38%109.23K	305.56%123.18K	-15.04%345.89K	-17.79%188.7K	-20.71%78.14K	48.88%48.68K
Gross profit	118.28%256.7K	51.29%563.41K	265.76%104.8K	-43.12%129.4K	187.42%243.95K	274.62%117.61K	-72.31%372.4K	134.22%28.65K	-36.66%227.49K	-70.93%84.87K
Operating expense	100.21%1.21M	-7.03%3.64M	8.15%1.29M	32.77%1.01M	-16.51%800.35K	-40.06%604.85K	-30.65%3.92M	-56.90%1.19M	-32.02%759.14K	0.64%958.65K
Selling and administrative expenses	151.85%1.1M	-17.95%2.6M	-3.43%781.55K	22.92%754.68K	-29.89%626.1K	-48.73%436.26K	-29.95%3.17M	-64.59%809.3K	-31.55%613.99K	27.31%893.06K
-Selling and marketing expense	143.50%228.96K	-14.86%241.7K	-154.08%-67.35K	555.36%183.06K	45.10%109.12K	68.00%94.03K	-4.12%283.89K	-49.55%124.54K	79.89%27.93K	248.14%75.2K
-General and administrative expense	154.14%869.75K	-18.26%2.36M	23.97%848.9K	-2.46%571.62K	-36.79%516.98K	-56.95%342.23K	-31.76%2.88M	-66.41%684.76K	-33.52%586.06K	20.29%817.86K
Research and development costs	33.68%29.52K	360.57%427.8K	351.53%303.41K	202.76%100.37K	103.88%1.94K	-48.10%22.08K	-74.15%92.89K	-59.61%67.2K	-50.43%33.15K	-150.91%-50K
Depreciation amortization depletion	-43.53%82.73K	-1.14%620.31K	-27.09%207.25K	36.46%152.84K	21.28%140.19K	26.75%146.51K	-18.07%627.44K	-7.59%284.26K	-26.73%112K	-24.38%115.59K
-Depreciation and amortization	-43.53%82.73K	-1.14%620.31K	-27.09%207.25K	36.46%152.84K	21.28%140.19K	26.75%146.51K	-18.07%627.44K	-7.59%284.26K	-26.73%112K	-24.38%115.59K
Provision for doubtful accounts	----	-145.89%-5.97K	----	----	----	----	--13K	----	----	----
Other operating expenses	----	----	----	----	--32.12K	----	--15.62K	----	----	----
Operating profit	-95.85%-954.25K	13.16%-3.08M	-1.79%-1.18M	-65.24%-878.49K	36.32%-556.4K	50.16%-487.25K	17.62%-3.54M	59.17%-1.16M	29.82%-531.65K	-32.27%-873.77K
Net non-operating interest income (expenses)	-281.80%-304.03K	-149.94%-661.45K	-115.80%-304.95K	-97.86%-102.59K	-327.70%-174.28K	-159.11%-79.63K	-98.80%-264.64K	-297.35%-141.31K	-68.70%-51.85K	-21.14%-40.75K
Non-operating interest expense	281.80%304.03K	149.94%661.45K	115.80%304.95K	97.86%102.59K	----	159.11%79.63K	98.26%264.64K	297.89%141.31K	67.77%51.85K	----
Total other finance cost	----	----	----	----	327.70%174.28K	----	----	----	----	--40.75K
Other net income (expenses)		-35,162.05%-567.72K					99.96%-1.61K
Gain on sale of security	----	-453.11%-8.91K	----	----	----	----	-106.73%-1.61K	----	----	----
Special income (charges)	----	---558.81K	----	----	----	----	--0	----	----	----
-Less:Other special charges	----	--558.81K	----	----	----	----	----	----	----	----
Income before tax	-121.97%-1.26M	-13.03%-4.31M	-57.57%-2.05M	-68.14%-981.08K	20.10%-730.69K	43.79%-566.88K	55.11%-3.81M	81.18%-1.3M	26.21%-583.5K	-31.73%-914.52K
Income tax
Earnings from equity interest net of tax
Net income	-121.97%-1.26M	-13.03%-4.31M	-57.57%-2.05M	-68.14%-981.08K	20.10%-730.69K	43.79%-566.88K	55.11%-3.81M	81.18%-1.3M	26.21%-583.5K	-31.73%-914.52K
Net income continuous operations	-121.97%-1.26M	-13.03%-4.31M	-57.57%-2.05M	-68.14%-981.08K	20.10%-730.69K	43.79%-566.88K	55.11%-3.81M	81.18%-1.3M	26.21%-583.5K	-31.73%-914.52K
Noncontrolling interests
Net income attributable to the company	-121.97%-1.26M	-13.03%-4.31M	-57.57%-2.05M	-68.14%-981.08K	20.10%-730.69K	43.79%-566.88K	55.11%-3.81M	81.18%-1.3M	26.21%-583.5K	-31.73%-914.52K
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders	-121.97%-1.26M	-13.03%-4.31M	-57.57%-2.05M	-68.14%-981.08K	20.10%-730.69K	43.79%-566.88K	55.11%-3.81M	81.18%-1.3M	26.21%-583.5K	-31.73%-914.52K
Diluted earnings per share	0.00%-0.01	0.00%-0.04	37.50%-0.01	-66.67%-0.01	0.00%-0.01	0.00%-0.01	50.00%-0.04	75.38%-0.016	25.00%-0.006	0.00%-0.01
Basic earnings per share	0.00%-0.01	0.00%-0.04	37.50%-0.01	-66.67%-0.01	0.00%-0.01	0.00%-0.01	50.00%-0.04	75.38%-0.016	25.00%-0.006	0.00%-0.01
Dividend per share
Accounting Standards	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP
Audit Opinions	--	Unqualified Opinion with Explanatory Notes	--	--	--	--	Unqualified Opinion with Explanatory Notes	--	--	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

DOSE Rapid Dose Therapeutics Corp

Rapid Dose Therapeutics Corp Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow